Core Viewpoint - The legal opinion letter from Haiwen & Partners outlines the achievements of the vesting conditions for the incentive plans of Anker Innovations Technology Co., Ltd. for the years 2022, 2023, and 2024, including the cancellation of certain restricted stocks and adjustments to grant prices [1][5][21]. Group 1: Vesting Conditions Achievements - The vesting period for the 2022 incentive plan is from July 12, 2025, to July 11, 2026, with a vesting ratio of 1/3 of the total restricted stocks granted [9][12]. - The 2022 incentive plan's third vesting condition has been achieved, allowing for the vesting of 1.441268 million shares to 249 eligible participants [12][23]. - The 2023 incentive plan's second vesting period is from July 25, 2025, to July 24, 2026, with a vesting ratio of 1/2 of the total restricted stocks granted [13][15]. - The 2023 incentive plan's second vesting condition has been achieved, allowing for the vesting of 1.188652 million shares to 144 eligible participants [15][23]. - The 2024 incentive plan's first vesting period is from July 16, 2025, to July 15, 2026, with a vesting ratio of 1/2 of the total restricted stocks granted [17][20]. - The 2024 incentive plan's first vesting condition has been achieved, allowing for the vesting of 2.007706 million shares to 281 eligible participants [20][23]. Group 2: Cancellations and Price Adjustments - A total of 186,639 shares of restricted stock will be canceled due to 175 participants from the 2022 plan, 49 from the 2023 plan, and 24 from the 2024 plan, who no longer meet eligibility criteria due to leaving the company [21][22]. - The grant price for the 2022 incentive plan has been adjusted from 27.71 CNY to 26.21 CNY per share [21][22]. - The grant price for the 2023 incentive plan has been adjusted from 40.46 CNY to 38.96 CNY per share [22]. - The grant price for the 2024 incentive plan has been adjusted from 40.02 CNY to 38.52 CNY per share [22].

北京海润天睿律师事务所 朝阳区建外大街甲14号广播大厦5层、9层、10层、13层、17层 邮政编码：100022 电话：010-65219696 传真：010-88381869 二〇二五年六月 北京海润天睿律师事务所 关于爱玛科技集团股份有限公司 部分股权激励限制性股票回购注销实施的法律意见书 致：爱玛科技集团股份有限公司 关于爱玛科技集团股份有限公司 部分股权激励限制性股票回购注销实施的法律意见书 中国·北京 北京海润天睿律师事务所（以下简称"本所"）接受爱玛科技集团股份有限 公司（以下简称"爱玛科技"或"公司"）的委托，担任公司"2024 年限制性 股票激励计划"（以下简称"本激励计划"）的法律顾问。根据现行有效适用的 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简 称"《管理办法》"）等有关法律法规的规定，为公司回购注销部分限制性股票 （以下简称"本次回购注销"）相关事项，出具本法律意见书。 为出具本法律意见书，本所律师审阅了《爱玛科技集团股份有限公司2024 年限制性股票激励计划（草案）》（以下简称"《激励 ...

证券代码：603486 证券简称：科沃斯 公告编号：2025-049 转债代码：113633 转债简称：科沃转债 科沃斯机器人股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购注销原因：科沃斯机器人股份有限公司（以下简称"公司"）于 2025 年 通过了《关于回购注销部分激励对象已获授但尚未解除限售的限制性股票的议案》。 鉴于公司 2024 年股票期权与限制性股票激励计划首次授予的邹晓静等 77 名激励对象 因离职已不再符合《上市公司股权激励管理办法》及公司《2024 年股票期权与限制 性股票激励计划（草案）》的相关规定继续参与公司激励计划的资格，公司拟对其持 有的已获授但尚未解除限售的 489,300 股限制性股票予以回购注销。 ●本次注销股份的有关情况 二、本次限制性股票回购注销情况 （一）本次回购注销限制性股票的原因及依据 象因辞职、公司裁员而离职，自情况发生之日起，其已获授但尚未行权的期权不得 行权，由公司注销，已获授但尚未解除限售的限制性股票不得解 ...

Core Viewpoint - The company announced the repurchase and cancellation of 14,000 restricted stocks due to one incentive object resigning, with a repurchase price of 9.47 yuan per share [1][6][10]. Summary by Sections Announcement Details - The company’s board approved the repurchase of restricted stocks at a meeting held on June 30, 2025, following the resignation of one incentive object [1][2]. - The total number of restricted stocks to be repurchased is 14,000 shares, which represents 0.01% of the total share capital of 114,739,776 shares as of June 29, 2025 [6][7]. Repurchase Price and Funding - The repurchase price for the restricted stocks is set at 9.47 yuan per share, totaling 132,580 yuan, which will be funded entirely from the company’s own funds [6][7]. Impact on Share Capital Structure - After the repurchase and cancellation, the company’s total share capital will decrease from 114,739,776 shares to 114,725,776 shares [7][9]. - The number of restricted shares will decrease from 2,156,103 to 2,142,103 shares, while the number of unrestricted shares remains unchanged at 112,583,673 [8]. Compliance and Approval - The repurchase has been authorized by the company’s third extraordinary general meeting in 2024, and no further shareholder approval is required [6][9]. - The supervisory board has confirmed that the repurchase complies with relevant regulations and will not adversely affect the company’s financial status or operational results [9][10].

Core Viewpoint - The legal opinion letter from Beijing Pu Hua Law Firm addresses the conditions for the second release of restrictions on the 2022 restricted stock incentive plan of Ruiskanda Technology Development Co., Ltd. and the repurchase and cancellation of certain restricted stocks due to unmet performance conditions [2][3][22]. Group 1: Legal Framework and Approval - The law firm was commissioned to provide legal services for the implementation of the 2022 restricted stock incentive plan, relying on relevant laws and the company's articles of association [2][3]. - The board of directors approved various resolutions related to the incentive plan, including the authorization for the board to handle related matters [7][12]. - The independent directors expressed their agreement with the implementation of the incentive plan [7][12]. Group 2: Repurchase and Cancellation of Restricted Stocks - The company will repurchase and cancel a total of 608.25 million shares of restricted stocks due to 25 incentive objects losing their eligibility and performance conditions not being met [15][22]. - The repurchase price for the restricted stocks was adjusted to 3.834 yuan per share, with a total repurchase fund of 16,675,983 yuan [21][22]. - The performance targets for the second release of restrictions were not achieved, leading to the cancellation of the corresponding restricted stocks [13][20]. Group 3: Performance Conditions - The performance assessment for the second release of restrictions was based on a revenue growth target of not less than 30% compared to 2021, with a trigger value of not less than 24% [13][16]. - The company's audited revenue growth for 2023 was below the required threshold, resulting in the failure to meet the performance conditions [20][22].

Group 1: Company Overview - Wuhan Junheng was established in 2012 and initially focused on customized optical communication products [2] - The company shifted to standardized civilian markets after 2017, leveraging its advanced Chip on Board (COB) technology for data center communication [2] Group 2: Performance and Growth - Wuhan Junheng achieved growth in Q1 2025, driven by the expansion into high-speed product markets, particularly with the increase in shipments of 400G and 800G products [3] - The company has received sufficient funding support since becoming a subsidiary of Huylv Ecological in February 2025, alleviating long-standing financial pressures [4] Group 3: Production Capacity and Supply Chain - The expansion of Wuhan Junheng's factory in April 2025 aims to meet the growing demand for silicon photonics products, with a new facility in Ezhou expected to be completed in the second half of 2025 [4] - Material supply for optical modules is currently sufficient to meet production demands, with no anticipated bottlenecks even with potential increases in output over the next 6-12 months [5] Group 4: Incentives and Future Plans - Huylv Ecological implemented a stock incentive plan in 2023 for executives and key personnel, followed by a new plan in 2025 targeting 45 core technical and business staff at Wuhan Junheng [4] - The company is focusing on production capacity enhancements in the Ezhou factory to address high-speed optical communication product demands, with future strategies to be adjusted based on market dynamics [7]

Core Viewpoint - The company has successfully met the conditions for the first unlock period of its 2022 restricted stock incentive plan, allowing 6,453,200 shares to be released for trading, which represents 0.7998% of the total share capital [1][4][14] Summary by Sections 1. Approval Process for the Incentive Plan - The board of directors approved the 2022 restricted stock incentive plan and its amendments, confirming the list of eligible participants [2][4] - The supervisory board verified the list of participants and the performance assessment methods related to the incentive plan [2][4] 2. Unlock Conditions Achievement - The first unlock period for the restricted stocks is defined as 24 months from the grant date, with the first unlock period allowing for the release of one-third of the granted shares [4][5] - The company achieved the following conditions for unlocking: - A compound annual growth rate (CAGR) of net profit of 9.62% from 2021 to 2023, exceeding the required 6% [5] - A weighted average return on equity (ROE) of 8.98%, surpassing the required 8.9% [5] - New product sales accounted for 31.32% of main business revenue, exceeding the 21% threshold [5] 3. Details of the Unlocking Process - A total of 713 participants are eligible to unlock their shares, with the total number of shares being 6,453,200 [1][4][14] - The unlocking will affect the company's share structure, reducing the number of restricted shares and increasing the number of freely tradable shares [12][14] 4. Legal and Financial Opinions - Legal opinions confirm that the unlocking process has complied with necessary approvals and regulations, ensuring the legitimacy of the unlocking conditions [13][14] - Independent financial advisors have also verified that the conditions for unlocking have been met and that the process does not harm the interests of the company or its shareholders [14]

Core Viewpoint - The company, Lanke Technology, is actively engaging in share repurchase and plans to issue H-shares for further capital raising and market expansion [1][2][3] Group 1: Stock Performance - As of June 27, 2025, Lanke Technology's stock closed at 80.15 yuan, down 1.74% from the previous week [1] - The stock reached a weekly high of 81.5 yuan and a low of 77.45 yuan [1] - The company's total market capitalization is 91.755 billion yuan, ranking 7th in the semiconductor sector and 151st among all A-shares [1] Group 2: Share Repurchase - The company announced its first share repurchase plan for 2025, with a total repurchase amount of 2 billion to 4 billion yuan [2] - As of June 23, 2025, the company has repurchased 450,000 shares, accounting for 0.04% of the total share capital, with a total expenditure of approximately 35.1176 million yuan [1][3] - The repurchase price range was between 77.79 yuan and 78.29 yuan per share [1] Group 3: Upcoming Events - Lanke Technology will hold its first extraordinary general meeting on July 7, 2025, to discuss several proposals, including the issuance of H-shares and amendments to the company's articles of association [2][3] - The company plans to issue H-shares on the Hong Kong Stock Exchange, with a maximum issuance not exceeding 9% of the total share capital post-issuance [2] - The funds raised from the H-share issuance will primarily be used for cutting-edge technology research in interconnected chips and global market expansion [2]

Core Viewpoint - The company has successfully completed its share repurchase plan, which was aimed at implementing an equity incentive program, with a total repurchase amount between RMB 30 million and RMB 60 million [1][3]. Summary by Sections Implementation of Share Repurchase - The company initiated its share repurchase on July 1, 2024, through a centralized bidding method, and has committed to disclosing the progress of the repurchase on a monthly basis [2]. Results of Share Repurchase - As of June 26, 2025, the company repurchased a total of 13,964,923 shares, representing 1.35% of the total share capital of 1,032,935,798 shares. The highest transaction price was RMB 3.15 per share, while the lowest was RMB 0.99 per share, with a total transaction amount of RMB 30,020,188 (excluding transaction fees) and an average repurchase price of RMB 2.15 per share [3]. Compliance and Impact - The share repurchase complies with relevant laws and regulations and will not significantly impact the company's financial, operational, or debt obligations. It also does not affect the control structure of the company [4]. Shareholder Transactions - During the repurchase period, there were no stock trading activities by the company's directors, supervisors, senior management, controlling shareholders, or actual controllers [6]. Compliance with Regulations - The company adhered to all regulatory requirements regarding the timing, quantity, and pricing of the share repurchase, ensuring no violations occurred during the process [7][8]. Changes in Share Capital - The repurchased shares will be used for an equity incentive plan, which has not yet been implemented. If the shares are not utilized within 36 months, the unutilized portion will be canceled, leading to a reduction in total share capital [9][10].

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to adopt an equity incentive program for its subsidiary, WuXi Biologics, which includes a stock option plan and a restricted stock unit plan aimed at attracting and retaining skilled personnel [2][7][30]. Group 1: Overview of the Equity Incentive Plan - The equity incentive plan consists of two independent programs: (1) a stock option plan and (2) a restricted stock unit plan [2][7]. - The total number of stock options and restricted stock units to be granted under these plans will not exceed 8% of WuXi Biologics' total shares (excluding treasury shares) as of the adoption date [3][8]. - As of the announcement date, WuXi Biologics has a total of 543,494,853 shares, with the group holding 63.43% of the shares [3][28]. Group 2: Initial Grant Details - The initial grant will involve issuing a total of 6.985 million stock options and 6.985 million restricted stock units to 279 qualified individuals, with an exercise price of HKD 50.25 per share for stock options and a vesting price of RMB 1 per restricted stock unit [3][24][25]. - The initial grant is subject to approval by WuXi Biologics' shareholders and will not constitute a related party transaction [4][10][27]. Group 3: Purpose and Conditions of the Plan - The purpose of the equity incentive plan is to attract, motivate, and retain skilled personnel, recognizing their contributions and encouraging them to enhance the value of WuXi Biologics [11][30]. - The plan's effectiveness requires approval from WuXi Biologics' shareholders and compliance with the Hong Kong Stock Exchange's listing rules [13][32]. Group 4: Financial Overview of WuXi Biologics - WuXi Biologics, established in February 2010 and listed on the Hong Kong Stock Exchange in September 2019, focuses on the research, production, and sales of monoclonal antibody drugs [28]. - As of December 31, 2024, WuXi Biologics reported total assets of RMB 1,059.75 million, total liabilities of RMB 758.39 million, and a net profit of RMB 82.05 million [29].